OPKO Health: agrees to sell BioReference business for $722,000,000

What happened

• OPKO Health filed an 8-K reporting that on Oct 14, 2026, OPKO and its wholly owned subsidiary BioReference Health, LLC entered into an Asset Purchase Agreement with Laboratory Corporation of America Holdings under which Seller agreed to sell and assign, and Buyer agreed to purchase and assume, certain assets of BioReference’s clinical and anatomic pathology laboratory testing business, including assets focused on clinical and women’s health testing services, urology, corrections and Seller’s proprietary 4Kscore prostate cancer test.

Key details

• Buyer will pay an aggregate purchase price of $722,000,000 in cash at closing, subject to certain adjustments based on Business revenues at closing.
• Buyer may pay up to $150,000,000 in additional cash over a period of up to 10 years based on revenue generated from sales of the 4Kscore test.
• Consummation is subject to customary closing conditions and HSR Clearance; the transaction is not subject to a financing condition.
• If the agreement is terminated under specified circumstances related to failure to obtain HSR Clearance or other required governmental approvals, Buyer would be required to pay a termination fee of $28,880,000.

Why it may matter

• Item reported: Item 1.01 — entry into a material definitive agreement (the Asset Purchase Agreement covering sale of certain BioReference assets and related terms).
• The filing does not show why the insider traded or why the company acted.